AC176 not checked

Accutar Biotechnology Inc

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Metastatic Castration Resistant Prostate Cancer (2 trials)
Main trialPhase 1
“This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least one prior systemic therapy. The main goals of this study are to: Evaluate the safety and tolerability of AC176, evaluate pharmacokinetics and preliminary antitumor activity of AC176”In the company’s words, NCT05673109 on ClinicalTrials.gov

Other drugs for Metastatic Castration Resistant Prostate Cancer

All 194 drugs for Metastatic Castration Resistant Prostate Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Terminated 8 Oct 2023 A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Phase 1Terminated 5 Mar 2024 A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow AC176

Following is part of Solo: you see every change to AC176 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in